BRPI0911871A8 - uso de partículas veículo sólidas para melhorar a processabilidade de um agente farmacêutico - Google Patents

uso de partículas veículo sólidas para melhorar a processabilidade de um agente farmacêutico Download PDF

Info

Publication number
BRPI0911871A8
BRPI0911871A8 BRPI0911871A BRPI0911871A BRPI0911871A8 BR PI0911871 A8 BRPI0911871 A8 BR PI0911871A8 BR PI0911871 A BRPI0911871 A BR PI0911871A BR PI0911871 A BRPI0911871 A BR PI0911871A BR PI0911871 A8 BRPI0911871 A8 BR PI0911871A8
Authority
BR
Brazil
Prior art keywords
pharmaceutical agent
carrier particles
solid carrier
improve processability
processability
Prior art date
Application number
BRPI0911871A
Other languages
English (en)
Inventor
A Mathias Anita
P Kearney Brian
M Koziara Joanna
M Menning Mark
Oliyai Reza
Yu Richard
G Strickley Robert
Original Assignee
Gilead Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40809930&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0911871(A8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Gilead Sciences Inc filed Critical Gilead Sciences Inc
Publication of BRPI0911871A2 publication Critical patent/BRPI0911871A2/pt
Publication of BRPI0911871A8 publication Critical patent/BRPI0911871A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
BRPI0911871A 2008-05-02 2009-05-01 uso de partículas veículo sólidas para melhorar a processabilidade de um agente farmacêutico BRPI0911871A8 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US4993508P 2008-05-02 2008-05-02
US15065209P 2009-02-06 2009-02-06
US15065509P 2009-02-06 2009-02-06
PCT/US2009/042607 WO2009135179A2 (en) 2008-05-02 2009-05-01 The use of solid carrier particles to improve the processability of a pharmaceutical agent

Publications (2)

Publication Number Publication Date
BRPI0911871A2 BRPI0911871A2 (pt) 2015-11-17
BRPI0911871A8 true BRPI0911871A8 (pt) 2018-03-06

Family

ID=40809930

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0911871A BRPI0911871A8 (pt) 2008-05-02 2009-05-01 uso de partículas veículo sólidas para melhorar a processabilidade de um agente farmacêutico

Country Status (27)

Country Link
US (1) US10039718B2 (pt)
EP (2) EP3006032A1 (pt)
JP (2) JP5722213B2 (pt)
KR (2) KR101659971B1 (pt)
CN (3) CN102123700A (pt)
AP (1) AP3089A (pt)
AU (3) AU2009242451C1 (pt)
BR (1) BRPI0911871A8 (pt)
CA (1) CA2720856C (pt)
CO (1) CO6321225A2 (pt)
CY (1) CY1117067T1 (pt)
DK (1) DK2296633T3 (pt)
EA (2) EA022950B1 (pt)
EC (1) ECSP10010636A (pt)
ES (1) ES2553897T3 (pt)
HK (2) HK1153670A1 (pt)
HR (1) HRP20151357T1 (pt)
HU (1) HUE026380T2 (pt)
IL (2) IL208614A (pt)
MX (2) MX342377B (pt)
NZ (1) NZ588978A (pt)
PL (1) PL2296633T3 (pt)
PT (1) PT2296633E (pt)
SG (2) SG190618A1 (pt)
SI (1) SI2296633T1 (pt)
WO (1) WO2009135179A2 (pt)
ZA (1) ZA201008007B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS54237B9 (sr) 2006-07-07 2019-07-31 Gilead Sciences Inc Modulatori farmakokinetičkih svojstava terapeutika
AR065439A1 (es) * 2007-02-23 2009-06-10 Gilead Sciences Inc Derivados de tiazoles 1,3 no condensados,composiciones farmaceuticas que los contienen y usos como agentes antivirales, en particular anti hiv.
SG182228A1 (en) * 2007-06-29 2012-07-30 Gilead Sciences Inc Therapeutic compositions and uses thereof
US20100331331A1 (en) * 2007-06-29 2010-12-30 Therapeutic Compositons And Use Thereof Therapeutic compositions and the use thereof
ES2553897T3 (es) 2008-05-02 2015-12-14 Gilead Sciences, Inc. El uso de partículas de vehículo sólido para mejorar la procesabilidad de un agente farmacéutico
UA108738C2 (uk) 2009-04-03 2015-06-10 Спосіб одержання інгібітора цитохром р450 монооксигенази та залучені проміжні сполуки
UA114075C2 (xx) 2010-11-19 2017-04-25 БАГАТОШАРОВА ТАБЛЕТКА, ЩО МІСТИТЬ РИЛПІВІРИН HCl, ЕМТРИЦИТАБІН І ТЕНОФОВІРУ ДИЗОПРОКСИЛФУМАРАТ
PT2705027E (pt) * 2011-05-02 2015-09-11 Gilead Sciences Inc Sais sólido de amorfo de cobicistat (gs-9350)
BR112014000290B1 (pt) 2011-07-07 2022-05-10 Gilead Sciences, Inc. Forma de dosagem oral de combinação de darunavir, processo para preparação de uma forma de dosagem oral e uso de granulado de darunavir
CN103732594A (zh) 2011-08-16 2014-04-16 吉联亚科学公司 替诺福韦艾拉酚胺(tenofovir alafenamide)半反丁烯二酸盐
WO2013106732A1 (en) 2012-01-12 2013-07-18 Gilead Sciences, Inc. Pharmaceutical compositions and methods for their preparation
WO2013116715A1 (en) 2012-02-03 2013-08-08 Gilead Sciences, Inc. Methods and intermediates for preparing pharmaceutical agents
CA2865491A1 (en) 2012-03-01 2013-09-06 Gilead Sciences, Inc. Spray dried formulations
JP2015534973A (ja) * 2012-10-23 2015-12-07 シプラ・リミテッド 抗レトロウイルス医薬組成物
US20160200716A1 (en) * 2012-12-26 2016-07-14 Assia Chemical Industries Ltd. Cobicistat dichlohydrate salt
DE102013205347A1 (de) 2013-03-26 2014-10-02 Hilti Aktiengesellschaft Additiv-Zusammensetzung für Amin-Härter, deren Verwendung sowie diese enthaltende Amin-Härterzusammensetzung
CN103230403A (zh) * 2013-04-23 2013-08-07 苏州谷力生物科技有限公司 一种抗艾滋病毒的组合型药物片剂
CA2931971A1 (en) 2013-11-29 2015-06-04 Mylan Laboratories Ltd. Amorphous cobicistat solid dispersion
WO2015145324A1 (en) 2014-03-25 2015-10-01 Mylan Laboratories Ltd Process for the preparation of cobicistat
US20160145344A1 (en) * 2014-10-20 2016-05-26 University Of Southern California Murine and human innate lymphoid cells and lung inflammation
US10166185B2 (en) * 2015-06-09 2019-01-01 J. Rettenmaier & Söhne Gmbh + Co Kg Excipient and oral solid dosage forms for oily drugs
WO2016201119A1 (en) * 2015-06-09 2016-12-15 J. Rettenmaier & Söhne Gmbh + Co Kg Excipient and oral solid dosage forms for oily drugs
TW201728582A (zh) 2016-01-28 2017-08-16 基利科學股份有限公司 結晶型
BR112019002120A2 (pt) 2016-08-08 2019-05-14 Hetero Labs Limited composição anti-retroviral de várias classes
US11045423B2 (en) 2016-08-08 2021-06-29 Hetero Labs Limited Anti-retroviral compositions
EA202191370A1 (ru) * 2018-12-14 2021-09-16 Фуджифилм Корпорэйшн Фармацевтическая композиция и способ ее получения
CN110251476B (zh) * 2019-08-01 2022-08-09 海思科制药(眉山)有限公司 一种恩曲他滨替诺福韦药物组合物
CN113425702B (zh) * 2021-06-25 2022-08-26 中国药科大学 应用微流控技术制备纳米颗粒、制备方法及装置和用途

Family Cites Families (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3400197A (en) * 1965-01-26 1968-09-03 Robins Co Inc A H Compressible sustained release pharmaceutical tablet lipid-colloidal silica gel matrix fragment granules
GB1241024A (en) 1968-10-29 1971-07-28 Boehringer Sohn Ingelheim Pharmaceutical tablet base and a process for its manufacture
BE768481A (fr) 1970-06-15 1971-11-03 Sumitomo Chemical Co Procede de production de nodules spheriques
CH586568A5 (pt) 1972-04-10 1977-04-15 Hoffmann La Roche
DE2845326C2 (de) * 1978-10-18 1985-05-23 Beiersdorf Ag, 2000 Hamburg Verwendung einer spezifischen mikrodispersen, amorphen, porösen Kieselsäure zur Herstellung von Digoxin enthaltenden Tabletten mit stark beschleunigter Wirkstoff-Freisetzung
US4603143A (en) * 1983-05-02 1986-07-29 Basf Corporation Free-flowing, high density, fat soluble vitamin powders with improved stability
GB8413191D0 (en) 1984-05-23 1984-06-27 Beecham Group Plc Pharmaceutical composition
FR2609958B1 (fr) 1987-01-27 1995-03-10 Honda Motor Co Ltd Dispositif de support pour roues arriere de motocyclettes
FR2631620B1 (fr) 1988-05-19 1990-07-27 Rhone Poulenc Chimie Nouvelle silice precipitee absorbante et composition a base de cette s ilice
US5696270A (en) * 1989-05-23 1997-12-09 Abbott Laboratories Intermediate for making retroviral protease inhibiting compounds
US5354866A (en) * 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
IE20010533A1 (en) 1990-11-20 2003-03-05 Abbott Lab Intermediates for preparing retroviral protease inhibiting compounds
GB9109862D0 (en) 1991-05-08 1991-07-03 Beecham Lab Sa Pharmaceutical formulations
ZA923641B (en) 1991-05-21 1993-02-24 Iaf Biochem Int Processes for the diastereoselective synthesis of nucleosides
KR100187990B1 (ko) 1992-12-29 1999-06-01 스티븐 에프. 웨인스톡 레트로바이러스성 프로테아제 억제 화합물 제조용 합성 중간체
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
WO1995005808A1 (en) * 1993-08-24 1995-03-02 Abbott Laboratories Oil-based tableting method
US5559158A (en) * 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
US5585115A (en) 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
US5948438A (en) 1995-01-09 1999-09-07 Edward Mendell Co., Inc. Pharmaceutical formulations having improved disintegration and/or absorptivity
GB9514464D0 (en) 1995-07-14 1995-09-13 Glaxo Lab Sa Medicaments
JP4064476B2 (ja) * 1996-03-29 2008-03-19 エラワン ファーマスーティカル リサーチ アンドラボラトリー カンパニー リミテッド 二酸化珪素を有する球状凝集した澱粉
US6348216B1 (en) * 1996-06-10 2002-02-19 Knoll Pharmaceutical Company Ibuprofen and narcotic analgesic compositions
US6361794B1 (en) * 1996-06-12 2002-03-26 Basf Corporation Method of making ibuprofen and narcotic analgesic composition
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US5939090A (en) * 1996-12-03 1999-08-17 3M Innovative Properties Company Gel formulations for topical drug delivery
JP4494539B2 (ja) * 1997-02-28 2010-06-30 ディーエスエム アイピー アセッツ ビー．ブイ． 流動自由な乾燥粒子
FR2767071B1 (fr) 1997-08-06 1999-09-10 Rhodia Chimie Sa Composition comprenant un liquide absorbe sur un support a base de silice precipitee
JP4027535B2 (ja) 1998-05-26 2007-12-26 エーザイ・アール・アンド・ディー・マネジメント株式会社 脂溶性薬物を含有した粉末
US6342249B1 (en) * 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
CA2311734C (en) * 2000-04-12 2011-03-08 Bristol-Myers Squibb Company Flash-melt oral dosage formulation
US20020076437A1 (en) 2000-04-12 2002-06-20 Sanjeev Kothari Flashmelt oral dosage formulation
US20030035834A1 (en) * 2000-05-26 2003-02-20 Pawan Seth Sustained release verapamil pharmaceutical composition free of food effect and a method for alleviating food effect in drug release
RU2281757C2 (ru) * 2000-09-19 2006-08-20 Дайити Фармасьютикал Ко., Лтд. Фармацевтическая композиция
US7056951B2 (en) * 2000-09-26 2006-06-06 Mutual Pharmaceutical Co., Inc. Stable solid dosage forms of amino acids and processes for producing same
US6524615B2 (en) * 2001-02-21 2003-02-25 Kos Pharmaceuticals, Incorporated Controlled release pharmaceutical composition
DE10112651A1 (de) * 2001-03-16 2002-09-19 Degussa Inhomogene Kieselsäuren als Trägermaterial
KR100568380B1 (ko) 2001-05-01 2006-04-05 화이자 프로덕츠 인코포레이티드 저 투약량 약학 조성물의 제조 방법
WO2002094255A1 (de) 2001-05-18 2002-11-28 Lonza Ag Verfahren zur herstellung fester formulierungen von natrium-3-hydroxy-3-methylbutyrat
DE10126163A1 (de) * 2001-05-30 2002-12-05 Degussa Pharmazeutische Zubereitungen
CN100579514C (zh) 2001-07-06 2010-01-13 生命周期药物公司 通过受控制的凝聚而制备颗粒物的方法以及提高生物利用度的方法
GB0123400D0 (en) * 2001-09-28 2001-11-21 Novartis Ag Organic compounds
US7815936B2 (en) * 2001-10-30 2010-10-19 Evonik Degussa Gmbh Use of granular materials based on pyrogenically produced silicon dioxide in pharmaceutical compositions
DE10153078A1 (de) 2001-10-30 2003-05-22 Degussa Verwendung von Granulaten auf Basis von pyrogen hergestelltem Siliciumdioxid in pharmazeutischen Zusammensetzungen
US20030206978A1 (en) * 2001-11-29 2003-11-06 Bob Sherwood Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
WO2003047551A1 (en) 2001-11-29 2003-06-12 Penwest Pharmaceutical Company Agglomerated particles including an active agent coprocessed with silicified microcrystalline cellulose
US6926906B2 (en) * 2002-02-20 2005-08-09 M./S. Strides, Inc. Orally administrable pharmaceutical formulation
PA8576201A1 (es) * 2002-07-10 2004-05-26 Pfizer Prod Inc Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
DE10250711A1 (de) * 2002-10-31 2004-05-19 Degussa Ag Pharmazeutische und kosmetische Zubereitungen
JP3567162B1 (ja) 2002-11-20 2004-09-22 日本たばこ産業株式会社 ４−オキソキノリン化合物及びそのｈｉｖインテグラーゼ阻害剤としての利用
DE60329318D1 (de) * 2002-11-20 2009-10-29 Japan Tobacco Inc 4-oxochinolinverbindungen und deren verwendung als hiv-integrase-inhibitoren
US7189416B2 (en) * 2002-11-23 2007-03-13 Glykon Technologies Group, Llc Method for stable and controlled delivery of (-)-hydroxycitric acid
DK1583542T3 (da) 2003-01-14 2008-09-22 Gilead Sciences Inc Sammensætninger og fremgangsmåder til antiviral kombinationsterapi
EP1596835A1 (en) * 2003-02-19 2005-11-23 H. Lundbeck A/S Method for preparation of an agglomerate using melt agglomeration
EP1601347A1 (en) 2003-02-19 2005-12-07 LifeCycle Pharma A/S Use of a silica or silica derivative as a sorption material
FR2851918B1 (fr) * 2003-03-06 2006-06-16 Poudre impregnee ameliorant la biodisponibilite et/ou la solubilite et procede de fabrication
JP4018664B2 (ja) 2003-04-30 2007-12-05 第一三共株式会社 安定化固形製剤
DE10337198A1 (de) * 2003-08-13 2005-03-17 Degussa Ag Träger auf Basis von Granulaten, die aus pyrogen hergestelltem Siliciumdioxiden hergestellt sind
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
JP2005075826A (ja) 2003-08-29 2005-03-24 Boehringer Ingelheim Internatl Gmbh 多孔質シリカ担体を含有する徐放性製剤
US20070122482A1 (en) * 2003-10-03 2007-05-31 Per Holm Method for preparing modified release pharmaceutical compositions
US20050096390A1 (en) * 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and pravastatin
US20070014846A1 (en) * 2003-10-10 2007-01-18 Lifecycle Pharma A/S Pharmaceutical compositions comprising fenofibrate and atorvastatin
CA2541382A1 (en) * 2003-10-10 2005-04-21 Lifecycle Pharma A/S A solid dosage form comprising a fibrate and a statin
CA2540984C (en) * 2003-10-10 2011-02-08 Lifecycle Pharma A/S A solid dosage form comprising a fibrate
US20050096391A1 (en) * 2003-10-10 2005-05-05 Per Holm Compositions comprising fenofibrate and rosuvastatin
US9173847B2 (en) * 2003-10-10 2015-11-03 Veloxis Pharmaceuticals A/S Tablet comprising a fibrate
US20050095287A1 (en) * 2003-10-29 2005-05-05 Matharu Amol S. Fosinopril composition
EP1729766A1 (en) * 2004-03-01 2006-12-13 LEK Pharmaceuticals D.D. Pharmaceutical formulation
MY142989A (en) 2004-03-10 2011-02-14 Bayer Schering Pharma Ag Stabilised supersaturated solids of lipophilic drugs
WO2005105040A2 (en) * 2004-04-26 2005-11-10 Micelle Products, Inc. Water-soluble formulations of fat soluble vitamins and pharmaceutical agents and their applications
MY134672A (en) 2004-05-20 2007-12-31 Japan Tobacco Inc Stable crystal of 4-oxoquinoline compound
EA013632B1 (ru) 2004-06-28 2010-06-30 Лайфсайкл Фарма А/С Пористые таблетки в качестве носителей для жидких композиций
US20060009603A1 (en) * 2004-07-09 2006-01-12 David Young Fibrillation-resistant polypropylene tape
AR045841A1 (es) 2004-09-28 2005-11-16 Richmond Sa Com Ind Y Financie Una composicion farmaceutica solida que comprende al tiazolil metil ester del acido [5s-(5r*, 8r*, 10r*,11r*)] -10- hidroxi-2- metil-5-(1-metiletil)-1-[2-(1-metiletil)-4-tiazolil]-3,6-dioxo-8,11-bis(fenilmetil)-2,4,7,12- tetraazatridecan-13-oico y un procedimiento para prepararla.
TWI375560B (en) 2005-06-13 2012-11-01 Gilead Sciences Inc Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same
TWI471145B (zh) 2005-06-13 2015-02-01 Bristol Myers Squibb & Gilead Sciences Llc 單一式藥學劑量型
US20070014854A1 (en) * 2005-07-15 2007-01-18 Ilan Zalit Novel granulation process
JP2007039338A (ja) 2005-07-29 2007-02-15 Hirofumi Takeuchi シリカ系複合顆粒
RU2008128424A (ru) 2005-12-14 2010-01-20 Сипла Лимитед (In) Фармацевтическая комбинация, включающая нуклеотидный и нуклеозидный ингибиторы обратной транскриптазы (такие как тенофовир и ламивудин) в различных частях дозы
JP2009521523A (ja) 2005-12-27 2009-06-04 ジュビラント・オルガノシス・リミテッド 口中溶解性医薬組成物およびその製造方法
DK1973529T3 (da) 2006-01-05 2011-09-12 Veloxis Pharmaceuticals As Fyldbar tablet, som er i stand til at falde hen
EP1990062A1 (en) * 2006-02-20 2008-11-12 ASAHI BREWERIES, Ltd. Granules, tablets and method of producing the same
MX2008012225A (es) * 2006-03-23 2008-12-03 Schering Corp Combinaciones de inhibidores de proteasa de virus de hepatitis c e inhibidores de isoenzima 3a4 del citocromo p450, y metodos de tratamiento relacionados con las mismas.
RS54237B9 (sr) * 2006-07-07 2019-07-31 Gilead Sciences Inc Modulatori farmakokinetičkih svojstava terapeutika
AU2007283196A1 (en) 2006-08-10 2008-02-14 Cipla Limited Antiretroviral solid oral composition
WO2008029417A2 (en) 2006-09-04 2008-03-13 Matrix Laboratories Limited Pharmaceutical formulation for use in hiv therapy
US7749537B2 (en) * 2006-12-04 2010-07-06 Scolr Pharma, Inc. Method of forming a tablet
AR065439A1 (es) * 2007-02-23 2009-06-10 Gilead Sciences Inc Derivados de tiazoles 1,3 no condensados,composiciones farmaceuticas que los contienen y usos como agentes antivirales, en particular anti hiv.
SG182228A1 (en) 2007-06-29 2012-07-30 Gilead Sciences Inc Therapeutic compositions and uses thereof
US20100331331A1 (en) 2007-06-29 2010-12-30 Therapeutic Compositons And Use Thereof Therapeutic compositions and the use thereof
WO2009037449A1 (en) 2007-09-18 2009-03-26 Cipla Limited Solid pharmaceutical compositions comprising one or more herpes virus inhibitors and one or more reverse transcriptase inhibitors
ES2553897T3 (es) 2008-05-02 2015-12-14 Gilead Sciences, Inc. El uso de partículas de vehículo sólido para mejorar la procesabilidad de un agente farmacéutico
SG2014007744A (en) * 2009-02-06 2014-05-29 Gilead Sciences Inc Tablets for combination therapy
EP2238979A1 (en) 2009-04-06 2010-10-13 LEK Pharmaceuticals d.d. Active pharmaceutical ingredient adsorbed on solid support
TW201728582A (zh) 2016-01-28 2017-08-16 基利科學股份有限公司 結晶型

Also Published As

Publication number Publication date
JP2011522790A (ja) 2011-08-04
WO2009135179A3 (en) 2011-05-19
EA201591353A1 (ru) 2016-01-29
KR20110015581A (ko) 2011-02-16
EP2296633A2 (en) 2011-03-23
HK1153670A1 (zh) 2012-04-05
CO6321225A2 (es) 2011-09-20
SI2296633T1 (sl) 2015-11-30
KR20160114728A (ko) 2016-10-05
HK1215679A1 (zh) 2016-09-09
AU2016250470A1 (en) 2016-11-17
BRPI0911871A2 (pt) 2015-11-17
CN102123700A (zh) 2011-07-13
CN104940937A (zh) 2015-09-30
AP3089A (en) 2015-01-31
CN103479584A (zh) 2014-01-01
ES2553897T3 (es) 2015-12-14
NZ588978A (en) 2013-01-25
JP2014012741A (ja) 2014-01-23
IL208614A0 (en) 2010-12-30
AP2010005429A0 (en) 2010-10-31
WO2009135179A2 (en) 2009-11-05
CY1117067T1 (el) 2017-04-05
CA2720856C (en) 2016-02-02
US10039718B2 (en) 2018-08-07
CA2720856A1 (en) 2009-11-05
PL2296633T3 (pl) 2016-03-31
SG10201609006WA (en) 2016-12-29
MX342377B (es) 2016-09-27
JP5722213B2 (ja) 2015-05-20
US20090324729A1 (en) 2009-12-31
AU2014221210B2 (en) 2016-08-18
KR101784647B1 (ko) 2017-10-11
HRP20151357T1 (hr) 2016-01-29
HUE026380T2 (en) 2016-06-28
AU2014221210C1 (en) 2017-06-01
ZA201008007B (en) 2011-10-26
ECSP10010636A (es) 2011-03-31
AU2009242451C1 (en) 2017-05-18
SG190618A1 (en) 2013-06-28
KR101659971B1 (ko) 2016-09-26
EP3006032A1 (en) 2016-04-13
EA201071173A1 (ru) 2011-08-30
IL208614A (en) 2016-09-29
PT2296633E (pt) 2015-12-04
DK2296633T3 (en) 2016-01-11
EP2296633B1 (en) 2015-09-30
EA022950B1 (ru) 2016-03-31
IL247417A0 (en) 2016-11-30
MX2010011963A (es) 2010-12-06
JP5925171B2 (ja) 2016-05-25
AU2009242451A1 (en) 2009-11-05

Similar Documents

Publication Publication Date Title
BRPI0911871A2 (pt) uso de partículas veículo sólidas para melhorar a processabilidade de um agente farmacêutico
BRPI1008793A2 (pt) composto, uso de um composto, e, composição farmacêutica
BRPI1016219A2 (pt) composto, composição farmacêutica, e, uso de um composto
BR112013008259A2 (pt) composto, composição farmacêutica, e, uso de um composto
AU2014221210A1 (en) The use of solid carrier particles to improve the processability of a pharmaceutical agent
BR112013015397A2 (pt) composto, composição farmacêutica, e, uso de um composto
BR112012002331A2 (pt) composição antiviral, composição farmacêutica e uso de quantidade efetiva de composição farmacêutica
BRPI0919942A2 (pt) Composto, composição farmacêutica, e, uso de um composto
BRPI0907562A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0921375A2 (pt) composto, composição farmacêutica, e, uso de um composto
BR112014013760A2 (pt) composto, composição farmacêutica e uso de um composto
BRPI0917579A2 (pt) composto, composição farmacêutica, métodos, e, uso de um composto
BRPI0921879A2 (pt) composto, composição farmacêutica , e, uso de um composto
BR112012000652A2 (pt) composições contendo partículas de liberação de agente de benefício
BR112013011448A2 (pt) composto, composição farnmacêutica, e, uso do composto
BR112014005669A2 (pt) composto, composição farmacêutica e uso de um composto
BR112012031226A2 (pt) composto, uso do composto, composição farmacêutica, e uso de composição farmacêutica
BR112014003567A2 (pt) composto, uso de um composto, e, composição farmacêutica
BRPI0906937A2 (pt) composto, composição farmacêutica, e, uso de um composto
BR112014013177A2 (pt) composto, composição farmacêutica e uso de um composto
BRPI1007186A2 (pt) composto, composição farmacêutica, e, uso de um composto
BRPI0917026A2 (pt) uso de sucralose como agente granulador
BRPI0919165A2 (pt) composição farmacêutica,e, uso de um composto
BRPI0915473A2 (pt) composto, composição farmacêutica, e, uso de um composto
BR112014013178A2 (pt) composto, composição farmacêutica e uso de um composto

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 11A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2564 DE 2020-02-27